MedTrace Logo

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

NCT04827875 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-12-27

No results posted yet for this study

Summary

To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

Conditions

  • Keloid
  • Scar
  • Incision
  • Excision Margin

Interventions

DRUG

AIV001

Intradermal

Sponsors & Collaborators

  • AiViva BioPharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2022-12-15
Completion
2022-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827875 on ClinicalTrials.gov